TSMHT
MYGN icon

Thurston Springer Miller Herd & Titak’s Myriad Genetics MYGN Stock Holding History

Thurston Springer Miller Herd & Titak’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-30
Closed -$266 – 1692
2025
Q1 		$266 Buy
+30
New +$360 ﹤0.01% 1620

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Thurston Springer Miller Herd & Titak's MYGN Position: Q2 2025 in Review

Thurston Springer Miller Herd & Titak sold out of Myriad Genetics (MYGN) in Q2 2025, closing a stake of 30 shares — an estimated $266 sold.

Thurston Springer Miller Herd & Titak first reported a position in MYGN in Q1 2025 and held it in 1 quarter. The position peaked at $266 in Q1 2025. 221 funds tracked by Wall St. Rank hold MYGN as of Q2 2025.

  • Thurston Springer Miller Herd & Titak reported no remaining Myriad Genetics position as of Q2 2025 after selling out during the quarter.
  • Thurston Springer Miller Herd & Titak sold 30 Myriad Genetics shares in Q2 2025, an estimated $266.
  • Thurston Springer Miller Herd & Titak first reported a position in Myriad Genetics in Q1 2025 and held it in 1 quarter.
  • Thurston Springer Miller Herd & Titak's Myriad Genetics position peaked at $266 in Q1 2025.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2025.

Based on Thurston Springer Miller Herd & Titak's 13F filing for Q2 2025, filed 7 Jul 2025.